Drug intelligence / Profile preview

PLS-4

Development stage: Preclinical
Lead developer: Primetime
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

**PLS-4** is a preclinical oncology candidate developed by Primetime Life Sciences in collaboration with Mayo Clinic. It is described as a product of Primetime's Metual synergetic mutual-prodrug platform, which covalently links two approved small-molecule drugs with proprietary linkers designed to remain stable in gastrointestinal fluids and release the parent drugs in plasma over time. The specific constituent drugs, molecular targets, route of administration, and detailed mechanism for PLS-4 have not been publicly disclosed. Reported development indications include acute myeloid leukemia and ovarian cancer. ([primetimelifesci.com](https://primetimelifesci.com/synergetic-mutual-prodrugs-platform-metual/))

Beyond the preview

Go deeper on PLS-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLS-4.

Explore the full profile